[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Pages 44284-44285]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-18486]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated April 20, 2010, and published in the Federal 
Register on April 26, 2010, (75 FR 21660), Mylan Pharmaceuticals Inc., 
781 Chestnut Ridge Road, Morgantown, West Virginia 26505, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of the basic classes of controlled 
substances listed in schedule II:

[[Page 44285]]



------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methylphenidate (1724).....................  II
Fentanyl (9801)............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances in 
finished dosage form (FDF) from foreign sources for analytical testing 
and clinical trials in which the foreign FDF will be compared to the 
company's own domestically-manufactured FDF. This analysis is required 
to allow the company to export domestically-manufactured FDF to foreign 
markets.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the 
registration of Mylan Pharmaceuticals Inc., to import the basic classes 
of controlled substances is consistent with the public interest, and 
with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated Mylan Pharmaceuticals Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic classes of controlled 
substances listed.

    Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-18486 Filed 7-27-10; 8:45 am]
BILLING CODE 4410-09-P